BREA, Calif. – (Feb. 9, 2010) – The Beckman Coulter Antibody Cocktail Preparation Workstation automatically combines antibodies and staining dyes from individual vials into tubes or vials staged on the company’s Biomek* NXp deck. Automating the multi-color flow cytometry analysis preparation process eliminates costly errors associated with manual preparation and improves efficiency. Complex multi-reagent, multi-panel antibody staining cocktails** are prepared with precision and accuracy. [more]
Winston-Salem, North Carolina—February 8, 2010— Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it has been awarded a grant of $304,000 from The Michael J. Fox Foundation for Parkinson's Research (MJFF). The grant is to fund a project entitled: “Development of an ?6*-selective Neuronal Nicotinic Receptor (NNR) Imaging Agent as a Parkinson’s Disease Biomarker” and is the second awarded to Targacept by MJFF in the last six months. [more]
OMAHA, Neb., Feb. 8 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO) announced today that it has completed a preliminary study with a leading pharmaceutical company that validates the use of its licensed COLD-PCR technology to detect colorectal tumor-associated KRAS mutations that determine efficacy of recently developed therapies. These were detected in plasma samples in which the mutation levels were too low for detection by standard DNA analysis methodologies such as Sanger sequencing. [more]
VENLO, The Netherlands, February 8/PRNewswire-FirstCall/ -- QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that its wholly owned subsidiary DxS has acquired the global and exclusive licence for biomarker PI3K from Johns Hopkins University to develop real-time-PCR and endpoint PCR assays. [more]
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 8, 2010 - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has awarded a Notice of Allowance for the “Soutschek and Manoharan” patent (Application No. 10/916,185), which covers certain chemically modified siRNAs of any length directed to any target, including siRNAs with sterol conjugates for in vivo delivery. [more]
WINSTON-SALEM, N.C.--(BUSINESS WIRE)--Feb 8, 2010 - Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it has been awarded a grant of $304,000 from The Michael J. Fox Foundation for Parkinson's Research (MJFF). The grant is to fund a project entitled: “Development of an alpha6*-selective Neuronal Nicotinic Receptor (NNR) Imaging Agent as a Parkinson's Disease Biomarker” and is the second awarded to Targacept by MJFF in the last six months. [more]
DENVER and NEW ORLEANS, Feb. 8 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC:CONX) (BULLETIN BOARD: CONX) , a worldwide developer and marketer of diagnostic test kits, and Tulane University, today announced a major extension of the collaborative effort to combat viral hemorrhagic fever (VHF), an effort that will generate an additional $800,000 in contract revenue for Corgenix over the life of the contract. [more]
SAN DIEGO, Calif., Feb. 8 /PRNewswire/ -- NexBio, Inc. today announced the issuance by the United States Patent and Trademark Office of United States Patent No. 7,645,448 entitled "Class of Therapeutic Protein Based Molecules". This patent covers NexBio's sialidase pharmaceutical compositions, including its lead compound DAS181 (Fludase®), and methods of treating or preventing viral infection by influenza and parainfluenza with such compositions. [more]
London and Palo Alto, CA, February 8, 2010 – Silence Therapeutics plc (AIM: SLN) today announced that the United States Patent and Trademark Office (USPTO) has issued the company a notice of allowance on a patent application directed to methods of treatment using a high-value therapeutic target in the area of oncology. [more]
Reno, Nevada and Westbrook, Maine (February 8, 2010) – Hamilton Robotics and Artel have announced that the Artel MVS® (Multichannel Verification System) has been successfully validated for use with Hamilton’s MICROLAB STAR and NIMBUS automated liquid handling workstations. [more]
LONDON and PALO ALTO, Calif., Feb. 8 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) today announced that the United States Patent and Trademark Office (USPTO) has issued the company a notice of allowance on a patent application directed to methods of treatment using a high-value therapeutic target in the area of oncology [more]
Heidelberg, Germany; February 08 2010: Affimed Therapeutics AG, the therapeutic TandAb antibody company, today announced the successful completion of the preclinical development of its lead product AFM 13 for the treatment of Hodgkin's lymphoma. Following promising preclinical data the company is now preparing the start of its first clinical study with AFM 13. [more]
BETHESDA, Md.--(BUSINESS WIRE)--Feb 5, 2010 - REGENERX BIOPHARMACEUTICALS, INC. (NYSE Amex:RGN) announced today that a research team in Washington, D.C. has found that dystrophin-deficient Mdx mice, treated twice a week for six months with Tβ4, showed a significant increase in skeletal muscle regenerating fibers compared to untreated mice. [more]
NEW YORK, Feb. 4 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research today announced more than $2.8 million in awards for 13 new projects to speed the discovery of biomarkers of PD. The development of biomarkers is of critical importance to increasing the speed and efficiency of PD therapeutic development, allowing scientists and clinicians to more accurately identify appropriate subjects for clinical studies, measure disease progression and monitor treatment effects in clinical trials. [more]
IPSWICH, Mass., Feb. 4 /PRNewswire/ -- As an important supplier to the Wellcome Trust Sanger Institute, New England Biolabs is pleased to announce that the Sanger Institute will use New England Biolabs as one of its suppliers for next-generation sequencing library construction reagents. [more]
TARRYTOWN, N.Y. & CORONADO, Calif.--(BUSINESS WIRE)--Feb 4, 2010 - Progenics Pharmaceuticals, Inc. today announced the presentation of preclinical data on a series of novel compounds that simultaneously blocked two critical pathways involved in the growth and survival of cancer cells. [more]
CLEVELAND--(BUSINESS WIRE)--Feb 4, 2010 - ChanTest has developed a new stem cell-derived human cardiomyocyte (SC-hCM) action potential assay for improved cardiac risk evaluation of drug candidates in pre-clinical development. [more]
SAN DIEGO, Feb. 4 /PRNewswire/ -- Fate Therapeutics, Inc. received a Notice of Allowance from the United States Patent and Trademark Office for U.S. Patent Application Number 10/997,146 entitled "Methods for Reprogramming Somatic Cells." Upon issuance, the patent will cover foundational induced pluripotent stem cell (iPSC) technology for identifying agents that enable the reprogramming of human somatic cells, including pluripotency genes, small molecules and biologics. [more]
WALTHAM, Mass., Feb. 3 /PRNewswire-FirstCall/ -- Repligen Corporation (NASDAQ:RGEN) announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office for a patent covering a recombinant form of Protein A which is identical in structure to the commercial form of Protein A from Staphylococcus aureus which is used in the production of many of the world's approved monoclonal antibodies. [more]
SEATTLE--(BUSINESS WIRE)--Feb 3, 2010 - NanoString Technologies, Inc., a privately held life sciences company marketing a complete solution for detecting and counting large sets of target molecules in biological samples, today announced that it has appointed William D. Young as Executive Chairman of its Board of Directors. [more]
Mergers & Acquisitions, Partnerships, & Collaborations 2010 – Review and Outlook
This PharmaLive Special Report analyzes the healthcare industry’s M&As of 2009, providing a comprehensive listing of companies’ M&A activity and detailing the top 20 deals within each of the Pharmaceutical, Biotechnology, Specialty, and Medical Device sectors, and previews potential M&A activity within the healthcare arena for 2010.
The introductory rate of $395 expires February 17, 2010.
